NASDAQ:KANG - iKang Healthcare Group Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$20.34 -0.03 (-0.15 %)
(As of 06/25/2018 11:55 AM ET)
Previous Close$20.32
Today's Range$20.30 - $20.37
52-Week Range$11.70 - $20.62
Volume47,372 shs
Average Volume605,784 shs
Market Capitalization$1.41 billion
P/E Ratio78.35
Dividend YieldN/A
iKang Healthcare Group logoiKang Healthcare Group, Inc., together with its subsidiaries, provides preventive healthcare solutions in the People's Republic of China. The company operates in two segments, Medical Examinations and Other Medical Services, and Dental Services. It offers a range of medical examinations, including internal, gynecology, ophthalmology, ENT, dental, lab tests, electrocardiogram, ultrasound, and X-ray examination items. The company also provides value-added services at selected medical centers, such as disease screening focusing on cancer screening, cardiovascular and chronic disease screening, and functional medicine testing; dental care comprising oral health, pediatric and cosmetic dentistry, orthodontics, and dental implants; outpatient services, which consists of acupuncture, Chinese medicine, gynecology, internal medicine, obstetrics, ophthalmology, pediatrics, urology, and minor surgery; and on-site healthcare management or clinical services. It primarily serves corporate and individual customers through a network of self-owned medical centers and the facilities of third-party service providers. As of July 28, 2017, it owned and operated a network of 108 self-owned medical centers in 33 cities of China, including Beijing, Shanghai, Guangzhou, Shenzhen, Chongqing, Tianjin, Nanjing, Suzhou, Hangzhou, Chengdu, Fuzhou, Changchun, Jiangyin, Changzhou, Wuhan, Changsha, Yantai, Yinchuan, Weihai, Weifang, Shenyang, Xi'an, Wuhu, Guiyang, Ningbo, Foshan, Jinan, Bijie, Qingdao, Wuxi, Kaili, Mianyang, and Hong Kong. The company was formerly known as China iKang Healthcare, Inc. and changed its name to iKang Healthcare Group, Inc. in February 2014. iKang Healthcare Group, Inc. is headquartered in Beijing, the People's Republic of China.

Receive KANG News and Ratings via Email

Sign-up to receive the latest news and ratings for KANG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Offices & clinics of medical doctors


Debt-to-Equity Ratio0.03
Current Ratio0.76
Quick Ratio0.74


Trailing P/E Ratio78.35
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$563.93 million
Price / Sales2.50
Cash FlowN/A
Price / CashN/A
Book Value$4.79 per share
Price / Book4.25


EPS (Most Recent Fiscal Year)N/A
Net Income$-11,250,000.00
Net Margins-3.07%
Return on Equity4.69%
Return on Assets2.18%


Outstanding Shares69,440,000

The Truth About Cryptocurrencies

iKang Healthcare Group (NASDAQ:KANG) Frequently Asked Questions

What is iKang Healthcare Group's stock symbol?

iKang Healthcare Group trades on the NASDAQ under the ticker symbol "KANG."

How were iKang Healthcare Group's earnings last quarter?

iKang Healthcare Group Inc (NASDAQ:KANG) issued its quarterly earnings results on Wednesday, August, 31st. The medical research company reported $0.04 EPS for the quarter. The medical research company earned $101.20 million during the quarter. iKang Healthcare Group had a positive return on equity of 4.69% and a negative net margin of 3.07%. During the same period in the previous year, the business posted $0.16 earnings per share. View iKang Healthcare Group's Earnings History.

When is iKang Healthcare Group's next earnings date?

iKang Healthcare Group is scheduled to release their next quarterly earnings announcement on Wednesday, September, 12th 2018. View Earnings Estimates for iKang Healthcare Group.

Are investors shorting iKang Healthcare Group?

iKang Healthcare Group saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 5,830,378 shares, an increase of 43.2% from the May 15th total of 4,070,395 shares. Based on an average trading volume of 702,089 shares, the days-to-cover ratio is currently 8.3 days. Currently, 8.8% of the shares of the company are sold short. View iKang Healthcare Group's Current Options Chain.

Who are some of iKang Healthcare Group's key competitors?

Who are iKang Healthcare Group's key executives?

iKang Healthcare Group's management team includes the folowing people:
  • Mr. Ligang Zhang, Chairman, CEO & Pres (Age 46)
  • Mr. Yang Chen, Chief Financial Officer (Age 47)
  • Ms. Feiyan Huang, COO & Director (Age 47)
  • Christy Xie, Director of Investor Relations
  • Mr. Hua Liu, VP of Sales (Age 40)

Has iKang Healthcare Group been receiving favorable news coverage?

News stories about KANG stock have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. iKang Healthcare Group earned a media sentiment score of 0.17 on Accern's scale. They also assigned news articles about the medical research company an impact score of 44.64 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are iKang Healthcare Group's major shareholders?

iKang Healthcare Group's stock is owned by a number of of institutional and retail investors. Top institutional investors include ZHANG LEE LIGANG (13.90%), ZHANG LEE LIGANG (13.90%), ZHANG LEE LIGANG (13.90%), Fosun International Ltd (6.66%), TOP FORTUNE WIN LTD. (13.00%) and Maso Capital Partners Ltd (2.49%). View Institutional Ownership Trends for iKang Healthcare Group.

Which institutional investors are selling iKang Healthcare Group stock?

KANG stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, State of Wisconsin Investment Board, SG Americas Securities LLC and California Public Employees Retirement System. View Insider Buying and Selling for iKang Healthcare Group.

Which institutional investors are buying iKang Healthcare Group stock?

KANG stock was acquired by a variety of institutional investors in the last quarter, including Kontiki Capital Management HK Ltd., Athos Capital Ltd, NINE MASTS CAPITAL Ltd, Maso Capital Partners Ltd, Kassirer Asset Management Corp, OMERS ADMINISTRATION Corp, BlackRock Inc. and Millennium Management LLC. View Insider Buying and Selling for iKang Healthcare Group.

How do I buy shares of iKang Healthcare Group?

Shares of KANG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is iKang Healthcare Group's stock price today?

One share of KANG stock can currently be purchased for approximately $20.34.

How big of a company is iKang Healthcare Group?

iKang Healthcare Group has a market capitalization of $1.41 billion and generates $563.93 million in revenue each year. iKang Healthcare Group employs 14,801 workers across the globe.

How can I contact iKang Healthcare Group?

iKang Healthcare Group's mailing address is B-6F SHIMAO TOWER 92A JIANGUO ROAD CHAOYANG DISTRICT, Beijing F4, 100022. The medical research company can be reached via phone at 86-10-5320-6688 or via email at [email protected]

MarketBeat Community Rating for iKang Healthcare Group (KANG)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  191
MarketBeat's community ratings are surveys of what our community members think about iKang Healthcare Group and other stocks. Vote "Outperform" if you believe KANG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KANG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.